Drugs / PLX5622
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01329991 Comparator | May → Oct 2011 | rheumatoid arthritis | Plexxikon | Completed | No outcome recorded |
| Phase 1 | NCT01282684 Comparator | Jan → Apr 2011 | — | Plexxikon | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLX5622 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01282684 ↗ |
| Action | Inhibit | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL3639728 ↗1“Fms kinase inhibitor” NCT01282684 ↗ |
| Modality | Small molecule | “small molecule” NCT01282684 ↗ |
| Route | Oral | “to be taken orally” NCT01282684 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL3639728 ↗ |